Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

D Davis, Ian; J Martin, Andrew; R Stockler, Martin; Begbie, Stephen; N Chi, Kim; Chowdhury, Simon; Coskinas, Xanthi; Frydenberg, Mark; E Hague, Wendy; G Horvath, Lisa; M Joshua, Anthony; J Lawrence, Nicola; Marx, Gavin; McCaffrey, John; McDermott, Ray; McJannett, Margaret; A North, Scott; Parnis, Francis; Parulekar, Wendy; W Pook, David; Neil Reaume, M; K Sandhu, Shahneen; Tan, Alvin; Hsiang Tan, T; Thomson, Alastair; Tu, Emily; Vera-Badillo, Francisco; G Williams, Scott; Yip, Sonia; Y Zhang, Alison; R Zielinski, Robert; J Sweeney, Christopher; Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, ENZAMET

doi:10.1056/NEJMoa1903835

Public

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Shared by NobleBlocks on Jul 11, 2019 • 12:00 AM UTC

Authors:

Ian D Davis

Andrew J Martin

Martin R Stockler

Abstract

BACKGROUND: Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with m...

Discussions